Thrive Capital’s Dr. Nworah Ayogu on Why Neuralink Is More Interesting Than SpaceX

Amid a decade of stagnant life expectancy despite forty trillion dollars in spending, a wave of biotech and AI startups is reshaping the U.S. healthcare landscape through vertical integration and novel technologies. Pioneers like Isomorphic Labs and Moderna are slashing drug discovery timelines and doubling success rates, while companies such as Fortel and Oscar Health leverage custom silicon and AI-driven data stacks to outperform legacy institutions. As the sector projects a rise to nine trillion dollars in annual spending, these innovations prioritize clinical augmentation and in-house safety processing to capture value across the entire care continuum.